Ronwin v. Bayer Corporation

332 F. App'x 508
CourtCourt of Appeals for the Tenth Circuit
DecidedJune 17, 2009
Docket08-8089
StatusUnpublished
Cited by9 cases

This text of 332 F. App'x 508 (Ronwin v. Bayer Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ronwin v. Bayer Corporation, 332 F. App'x 508 (10th Cir. 2009).

Opinion

ORDER AND JUDGMENT *

PAUL KELLY, JR., Circuit Judge.

Edward Ronwin appeals pro se the dis- . trict court’s grant of summary judgment in favor of Bayer Corporation on his claims for negligence, strict liability, and breach of implied warranty. Exercising jurisdiction under 28 U.S.C. § 1291, we affirm.

Background

Dr. Ronwin filed a complaint against Bayer in September 2001, alleging that he was injured by cerivastatin, a prescription drug in the “statin” family that was manufactured and sold by Bayer under the name “Baycol.” The United States Food and Drug Administration (FDA) first approved Baycol for the treatment of high cholesterol in 1997. Plaintiff began taking Baycol for that purpose on or about January 10, 2001, when he was almost 77 years old. He alleges that a short time later he *510 began experiencing a number of physical symptoms, including pain in his left shoulder, thighs, and back, blurred vision, and gait problems. He stopped taking Baycol on or about August 8, 2001. He claims that his blurred vision and gait problems receded after he ceased taking Baycol, but that his other symptoms persisted. Dr. Ronwin was diagnosed in 2003 with a torn left rotator cuff, which he had surgically repaired.

Bayer voluntarily removed Baycol from the market on August 8, 2001, citing a risk of rhabdomyolysis 1 as a serious, potentially fatal adverse effect of the drug. Dr. Ronwin and thousands of other plaintiffs sued Bayer, claiming that various injuries resulted from their ingestion of Baycol. 2 As of 2003, Bayer had settled close to 1,000 of the claims involving Baycol. See In re Baycol Prods. Litig., 218 F.R.D. 197, 210 (D.Minn.2003).

In support of his claims, plaintiff proffered his own expert testimony and the expert testimony of Dr. Raul G. Reyes, as summarized in expert reports submitted to the district court. After discovery was completed, Bayer filed a summary judgment motion arguing there was no evidence establishing that Baycol caused plaintiff to suffer any injury. More specifically, Bayer contended that plaintiffs proffered expert testimony was inadmissible under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), because neither witness was qualified to offer an expert opinion and their methodologies were not reliable. The district court granted Bayer’s motion, excluding plaintiffs proffered expert testimony and granting summary judgment in favor of Bayer on all claims.

Applicable Law and Standards of Review

In this diversity action “the substantive law of the forum state governs the analysis of the underlying claims, including specification of the applicable standards of proof, but federal law controls the ultimate, procedural question whether [summary judgment] is appropriate.” Specialty Beverages, L.L.C. v. Pabst Brewing Co., 537 F.3d 1165, 1175 (10th Cir.2008). Thus, we apply federal law in reviewing de novo the district court’s grant of summary judgment in this case. See Hollander v. San doz Pharm. Corp., 289 F.3d 1193, 1214 (10th Cir.2002). Summary judgment is appropriate “if the pleadings, the discovery and disclosure materials on file, and any affidavits show that there is no genuine issue as to any material fact and that the movant is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c).

The district court’s grant of summary judgment in favor of Bayer rested on two antecedent rulings. First, the district excluded the testimony of both of plaintiffs experts. “The admissibility of expert testimony is governed by Rule 702 of the Federal Rules of Evidence.” United States v. Benally, 541 F.3d 990, 994 (10th *511 Cir.2008), cert. denied, — U.S. —, 129 S.Ct. 1020, 173 L.Ed.2d 309 (2009).

We review de novo the question of whether the district court performed its gatekeeper role and applied the proper legal standard in admitting an expert’s testimony. We then review for abuse of discretion the trial court’s actual application of the gatekeeper standard in deciding whether to admit or exclude an expert’s testimony.

Miller v. Pfizer, Inc., 356 F.3d 1326, 1335 (10th Cir.2004) (quotation and brackets omitted). In reviewing a district court’s application of the second step of this standard, we afford substantial deference to a court’s exclusion of expert opinion evidence under Daubert. Hollander, 289 F.3d at 1204. “Under the abuse of discretion standard, a trial court’s decision will not be disturbed unless the appellate court has a definite and firm conviction that the lower court made a clear error of judgment or exceeded the bounds of permissible choice in the circumstances.” Id. (quotation omitted). 3

In its second ruling leading to its grant of summary judgment, the district court held that, under Wyoming law, plaintiff was required to present expert testimony in order to establish that Baycol caused his injuries. Plaintiff does not challenge the district court’s application of Wyoming law in deciding this issue.

Exclusion of Expert Testimony

The proponent of expert testimony bears the burden of showing that its proffered expert’s testimony is admissible. Ralston v. Smith & Nephew Richards, Inc., 275 F.3d 965, 970-71 n. 4 (10th Cir.2001). F.R.E. 702 “imposes upon the trial judge an important ‘gate-keeping’ function with regard to the admissibility of expert opinions.” Ralston, 275 F.3d at 969. In this role, a district court should apply a two-step analysis, determining first whether an expert is qualified to render an opinion by ‘“knowledge, skill, experience, training, or education,’ ” and second, whether the expert’s opinions are “ ‘reliable’ ” under Daubert. Id. (quoting F.R.E. 702).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
332 F. App'x 508, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ronwin-v-bayer-corporation-ca10-2009.